MDCX News & Events

"During the first quarter of 2026, Medicus continued to execute on its transformation into a diversified clinical-stage biotechnology company, highlighted by expanded positive Phase 2 SkinJect data, advancement of Teverelix into additional clinical development pathways, and continued expansion of our regulatory and strategic initiatives," stated Raza Bokhari, Medicus' Executive Chairman & CEO. "We believe the growing strength of our clinical datasets, combined with expanded financing flexibility and continued development of AI-enabled clinical capabilities, positions the Company to pursue multiple value-driving milestones in dermatologic oncology, prostate cancer, acute urinary retention, and rare disease indications throughout 2026 and beyond."

Medicus Pharma announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase 2 SKNJCT-003 study evaluating safety and efficacy of doxorubicin microneedle Array to treat nodular basal cell carcinoma of the skin. The expanded central pathology-verified efficacy analysis of 69 participants showed a progressive, dose-dependent improvement, with the 200microgram cohort achieving the highest clinical and histological clearance rates by day 57 vs. device-only control. The company said the dataset, which also confirmed a favorable safety and tolerability profile without drug-related serious adverse events or systemic doxorubicin toxicity, supports a registrational path and planned end-of-Phase 2 discussions with the FDA. "We are encouraged by these additional findings in the expanded analysis, which we believe meaningfully strengthens the clinical and regulatory foundation of the SKNJCT-003 Program," said Raza Bokhari, chairman and CEO of Medicus.

Medicus Pharma announced that CEO Raza Bokhari, along with the Medicus leadership team, conducted a series of meetings on Capitol Hill with senior lawmakers across key healthcare committees to advance support for Orphan Drug Designation for SkinJect for Gorlin Syndrome and the rare disease pediatric FDA voucher program. "Our engagement with policymakers reflects a clear alignment around accelerating access to innovative therapies for patients with significant unmet need," said Raza Bokhari, executive chairman and CEO of Medicus. "We believe SkinJect has the potential to shift the treatment paradigm in Gorlin Syndrome by offering a localized, repeatable, non-surgical approach."